Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've made an absolute killing on CSE. Listen to their CC if you haven't done so.
Someone sold 100K at $4.80. Looks like a hedge is exiting. Wonder how many shares they need to unload?
I can't believe the lack of buying after the presentation except to think investors are waiting for the FDA decision for Androxal. We may have also gotten selling from traders who were hoping for a quick bounce and then they had to sell when it didn't materialize.
My thoughts, time to load the old wagon.
Is todays replay available? I can't locate the link.
Nothing like a 6% slide on above average volume to start the week. Why would you sell or short with the Dyloject approval announcement so close at hand?
Thats a pretty funny post.
The stock needs a fund to support the price and increase their position on weakness. The only thing we've got is a bunch of little guys running for the exits.
Wish I had waited till today to buy a few more shares. I guess the goal is to break $10.00.
Don't take one of my posts and turn it around since your trying to scare investors.
<<<Partnership or a Pipe is also a possibility come next Monday.>>>
There is a possibility of a buy-out for a couple billion on Monday also, but that doesn't make it worth posting on this board.
If in fact they did announce a pipe for 5 million shares at $10 as you've suggested then that would be great news in my book.
I've made a lot more money trading stocks from your "High/Yield" board then my biotechs with less headaches. I keep laughing about CSE, up over $2 share in a few weeks, and I get a .60 dividend on the 17th.
I love JAV's management so I'm still buying eventhough I hate watching the daily trading.
I would hold a bigger position in JAV, but I can't take the daily swings on low volume. I hate seeing a big decrease in my Unrealized profit/loss's and realize that JAV traded 10K shares. It just ticks me off.
Ok, had to get it off my chest.
CapitalSource Inc. (CSE): Takeaways from Financials Conference
Stock Rating: 1-Overweight
Sector Rating: 1-Positive
Price: US$ 16.30
Price Target: US$ 32.00
Current Year EPS: 2.65
Next Year EPS: 2.95
Market Cap: US$ 2901 (m)
Yesterday, we had the opportunity to hear from CapitalSource's CEO, John Delaney. CEO Delaney reiterated
that the company's liquidity is sound and highlighted a new deal of just over $1 billion in term financing of its
commercial real estate loans. In addition, management discussed the potential benefits of the TONE deal,
including goals of ramping up deposit based funding while shrinking the TONE asset base, which should allow
for considerably lower cost of funding for the entire company. This coupled with the tax advantages that its
REIT status allows, should enable the company higher ROEs longer term. Management expects the deal to
close during the fourth quarter at the same terms as were agreed upon at the time of the deal announcement.
Overall, we continue to believe that CSE will meet its 2007 dividend guidance of $2.40, which represents a
dividend yield of more than 14%.
After accounting for slightly slower growth and higher funding costs versus our previous estimates, we are
lowering our 3Q07 and 2007 adjusted EPS estimates by $0.02, and $0.05 to $0.67 and $2.65, respectively. We
also adjusted our 2008 EPS estimate by $0.03 to $2.95.
Thomas, I was glad to see that RPRX is conducting a conference call. JP must be reading my posts.
Nerf, I think we're all just a little frustrated. I'll feel a lot better once the FDA meeting has concluded.
Keep up the good work on the board.
What are you talking about, "QOL's are not a problem"? Its not a positive. It adds time & expense designing and conducting a trial. There's always the chance of not meeting stat significance since your dealing with subjective data.
I think its crazy for the FDA to ask for QOL's, but it wouldn't surprise me.
Nerf, I don't understand the part about the FDA saying "we don't know what you need for approval." Thats the whole point for the FDA meeting next month, to define whats necessary for approval. Have you ever seen an instance where the company made such a statement?
I'm not saying the stock price will suffer once they do a financing, its before the financing that I worry about. The last time RPRX raised money it occurred right after the release of clinical data and a lot of excitement was surrounding the programs.
The same thing could happen if RPRX decides to raise money, but it would help if the Androxal program did not need QOL's to obtain approval.
If RPRX was sitting on a $100 million then the financing issue would not be a question and investors could concentrate on the pipeline. RPRX is the same as every small biotech, when investors can't look for the release of data in the near term they start concentrating on the negatives.
<<<<With only a year of cash, how can you wait - 9 months from now could be MUCH worse.>>>
Exactly, RPRX is in good shape if the FDA decides they don't need libido studies to obtain an approval for Androxal, however, at what price would RPRX do another financing if QOL's are needed?
The share price is going to suffer as investors concentrate on the finances rather then the pipeline's potential.
CORT, but if I'm paying someone and they tell me to wait before I invest in a company then its hard not to listen. I realize hindsight is 20/20, but I also can't give them any credit.
You may not worry about it, but the market is in a wait and see mode. Investors start saying "why should I buy now when the stock may be on sale in a few months." I know its a stupid way of thinking, but when your considering several stocks then it plays a part in your investment decision.
This is why I stress the importance of getting the message out to investors.
Cort -up over $2.00 today. Geeez, and my newsletter told me not to get to excited about the stock. Heck, I'd be doing cartwheels.
Corcept Therapeutics Receives FDA Notification Opening IND for CORLUX(R) for the Treatment of Cushing's Syndrome
Tuesday September 11, 9:00 am ET
MENLO PARK, CA--(MARKET WIRE)--Sep 11, 2007 -- Corcept Therapeutics Incorporated (NasdaqCM:CORT - News) today announced that it has received notification from the Food and Drug Administration (FDA) that the FDA has opened the Investigational New Drug application (IND) for CORLUX for the treatment of Cushing's Syndrome. CORLUX is a cortisol receptor (GR-II) antagonist.
ADVERTISEMENT
In July 2007, the Company announced the receipt of Orphan Drug Designation for CORLUX for the treatment of Cushing's Syndrome. Drugs that receive Orphan Drug Designation obtain seven years of marketing exclusivity from the date of drug approval as well as tax credits for clinical trial costs, marketing application filing fee waivers and assistance from the FDA in the drug development process.
In the communication regarding the opening of the IND, the FDA indicated that a single study may provide a reasonable basis for the submission of a New Drug Application (NDA) for Corlux for the treatment of Cushing's Syndrome, which allows us to initiate the 50-patient open label study defined by the protocol submitted with the application for the IND. Corcept has begun qualifying potential sites for this study and expects to open the trial for enrollment late in the fourth quarter of 2007.
Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer, commented, "We are pleased that the FDA has allowed us to open our IND for CORLUX for the treatment of Cushing's Syndrome and to initiate the Phase 3 protocol included in the IND submission. We look forward to advancing a potential treatment for this rare illness."
http://biz.yahoo.com/iw/070911/0300405.html
Spartex, forget that I mentioned AIS. Looks like the conference call was a non-event.
Nerf, there is a reason the stock price continues to show weakness and I place the blame squarely on JP. The initial plan was to partner Androxal and use those funds to support the development of Proellex. BSR anticipates that RPRX will not partner/sell the pipeline till they have conducted additional clinical studies.
How did BSR come to that conclusion before investors such as myself since JP has not conducted any presentations? He opened his mouth and thats his problem.
What other information is he releasing is what scares me. When they decide to go back to the markets for additional money I don't want to be the last to know.
He does not support the individual investor so I have to invest accordingly no matter what potential the pipeline holds.
Just my opinion since you asked.
"birds nest on the ground" You have a completely different view then me.
I'm not investing another dollar in RPRX until I get a better idea of the clinical/business strategy.
OT- Spartex, tomorrow could be a great time to buy AIS depending on what is said during the BPA conference call, 8:45 E. They get royalties & milestone payments for LibiGel.
I'm looking for bargains & staying away from anything thats been linked to liquidity risk from the mortgage mess. That criteria would rule-out VRTB as a possible investment.
If your looking for a stock, buy "ZIXI". I bet its a $5 or $6 stock this time next year.
CSE, nice buying opportunity today. Fund must be raising cash for margin requirements. .60 dividend, ex-date Sept. 17th
JAV
<<<If intranasal ketamine works, there is a possibility that the whole VA/military treatment system will attempt to move away from the use of opiate meds.>>>
The nasal ketamine will not be marketed as a replacement for opioid meds. If you incurred a traumatic injury in the battlefield then a large dose of an opioid may decrease your blood pressure & respirations. The nasal ketamine does not have the same effects, blood pressure & respirations are maintained in addition to the faster pain relief.
The same thing holds true for emergency situations. EMT's don't have to fool around with gaining IV access before they can make the pt. more comfortable. Of course the pt. may not know who they are after the ketamine treatment, but at least their not screaming their head off.
Actually JAV says the ketamine dosage is very small so I don't know if individuals experience the dissociative effects normally seen with the administration of ketamine.
Do you know if RPRX will be presenting at any conferences in the next few months?
I invested in BKCC after seeing your mention on the Bio-tech value board & listening to the CC. Nice to see the Street.coms mention today. I've thought about adding some more shares, but was worried that investors would sell after the "Date of Record".
That was pretty funny. I mentioned BDSI on the biotech value board and no one responded. Have you ever looked at the company? They signed a nice partnership agreement today with MEDA. $30 million upfront and another $30 million on FDA approval. Only $79 million market cap. BDSI plans to file an NDA this qtr. and MEDA is pursuing an EU application.
http://www.meda.se/english/news/year_2007/meda_acquires_exclusive_rights.pdf
BDSI - Have you looked at the company? Market caps only $78 million. They plan to expand the indications for Bema fentanyl if it gets approval.
"9:37AM BioDelivery Services secures U.S. commercial partnership for BEMA fentanyl with Meda AB (BDSI) 4.40 +0.40 : Co announces it has entered into an exclusive and perpetual license and related supply agreement with Meda for the U.S., Canadian and Mexican commercialization rights to BDSI's flagship BEMA Fentanyl product for the treatment of "breakthrough" cancer pain. Under this agreement, Meda will be responsible for the marketing and distribution of BEMA Fentanyl in the U.S., whose launch is anticipated in late 2008. In addition, Meda will be responsible for the management of the post-NDA approval clinical development program. Financial Aspects of the Partnership: 1st milestone: $30 mln upon closing which is contingent upon antitrust approval by the Federal Trade Commission, which typically occurs within 30 days of filing. -- 2nd milestone: $30 mln upon receipt of FDA approval, which is anticipated in late 2008. Royalty: BDSI to receive a significant double digit royalty on net sales. Guaranteed minimum annual royalties, based on low sales, exist during the first 7 years. -- Sales milestones: A total of $30 mln payable at: -- $10 mln when annualized sales exceeds $75 mln-- $10 mln when annualized sales exceeds $125 mln -- $10 mln when annualized sales exceeds $175 mln-- A gross margin above 70% is secured for Meda."
Looks like the stock is under accumulation. Someone continues to play around with the stock price, but I'm thinking their just trying to hide the buying. Where is the PR about UK approval?
If Recession Comes, You Can Still Build Wealth: John F. Wasik
By John F. Wasik
Sept. 4 (Bloomberg) -- If the U.S. housing bust triggers a recession, you can still profit in the financial markets.
Investment advisers tell their clients to buy bonds when the stock market is in a prolonged tailspin.
The conventional wisdom is that about 40 percent of your portfolio should be in bonds, yet that wouldn't give you complete sanctuary since corporate and mortgage debt has been pummeled as corporate borrowing costs increased when asset-backed securities were contaminated by defaulted subprime mortgages.
While Treasuries are certainly profitable if rates drop, you will need an extra layer of insulation in your equity holdings -- earnings-rich stocks that pay dividends and are priced lower relative to their peers. Finding growth outside the U.S. is also essential.
One school of investing says you will suffer less volatility and gain income through high-dividend stocks in tandem with bonds. Another desirable trait that could be added to that philosophy: established non-U.S. companies.
For now, a select group of dividend-growing non-U.S. stocks appears to have dodged the maelstrom triggered by subprime mortgage woes. Most are going about their business conservatively and are glad to reward investors with consistent dividends at reasonable share prices.
Vodafone's Return
One example is Vodafone Group Plc, the world's largest mobile-phone company. The stock has had a total return of 47 percent in the past year, and sports a dividend growth rate of 32 percent over the past half-decade and an estimated price-earnings ratio of 14.4, according to Bloomberg data through Aug. 31.
A similar company is Manulife Financial Corp., Canada's largest insurer by assets, which has had a total return of 16 percent. With a P/E ratio of 14.6 and dividend growth rate of 25 percent, the firm has been untouched by the U.S. mortgage and housing meltdown.
You can do even better. I ran a search on my Bloomberg to determine which stocks posted dividends of 2 percent or better; were bargains with price-earnings ratios of 10 or lower; and were up at least 10 percent this year. I turned up 622 companies.
The figure would have been higher if the bubble-like Chinese markets were included in the search. Most of the picks on this screen are outside of the U.S.
Picking individual stocks that are bucking the U.S. slump isn't the goal. And waltzing blindly into a single security or sector to grab dividends is often perilous. You would do much better if you held a large basket of these kinds of companies.
Flight From REITs
Jumping into one dividend-rich sector isn't the answer, either. Just look at the recent decline in Real Estate Investment Trusts, which not only have paid generous income, they gained ground during the last market downturn.
Investors have been fleeing REITs, and mutual funds that invest in them, because of concerns that the U.S. home-sales decline will spread to the commercial market.
REITs have climbed 80 percent over the past five years, as measured by the Bloomberg REIT Index. Now they seem to be headed south. The index slid 16 percent during the last six months.
Of course, there's nothing wrong with focusing on income. If you are within two years of college tuition bills or a property down payment, capital preservation is a must.
In that case, take a look at federally insured certificates of deposit. Yields range from 4.85 percent to 5.50 percent, depending on the term of the certificate, according to BanxQuote, a savings service.
Overseas Growth
One common mistake is to focus too much on one's home country and ignore the growth occurring from Dublin to Taipei.
Mutual funds that have thrived outside the U.S. market include the Janus Overseas and the American Century International Opportunities funds.
American Century is up 18 percent this year while the Janus fund has climbed 11 percent.
Either fund would be a good choice to represent non-U.S. stocks as they have beaten more than 90 percent of their peers.
For an even broader sampling of world markets, consider the Vanguard Total International Stock Index Fund. It invests in three other Vanguard index offerings covering European, Pacific and emerging markets and is a fixture in my Roth 401(k) retirement account.
Are you nearing retirement or just risk-averse? After all, one objective is to reduce your stock investments and other risky assets by diversifying.
Diversify in Bonds
Say you wanted to increase your bond holdings and invest in a wide variety of debt. A well-diversified choice would be the Vanguard Total Bond Market Exchange-Traded Fund.
It aims to track the Lehman Brothers Aggregate Bond Index, a big basket of taxable U.S. bonds. A similar vehicle is the iShares Lehman Aggregate Bond Fund.
Neither fund will thrill you with its returns over the past year, although performance isn't the point, as these kinds of funds are income-focused.
Why even consider these vehicles? As the U.S. stock market struggles to stay in positive territory -- the Standard & Poor's 500 Index has risen about 4 percent this year -- the iShares fund has gained 3 percent. That's some consolation in a turbulent climate for stocks.
Don't let gloomy market forecasts put you off your main mission of trying to capture growth and income. There's more safety in numbers, that is, large baskets of different kinds of securities.
http://www.bloomberg.com/apps/news?pid=20601039&sid=aI3fQ2cK7RZI&refer=home
BKCC, .42 share dividend for stockholders of record Sept, 14th. Business outlook is positive going forward since they can take advantage of credit difficulties.
<<<<<Proellex has not demonstrated any of the Endometrium changes which were a huge concern for Asoprisnil, even before the pulsing scheme commenced>>>>
From the July/25th PR.
"Most prominent were the presence of non-uniform cystic dilatation of glands similar to the histological pattern recently described for women treated with other Progesterone Receptor Modulators (PRMs) such as asoprisnil, mifepristone and CBD 2914 (VA2914)3,4,5. The glandular epithelium within these cysts varied in appearance, but contained non-physiologic combinations of poorly developed secretory activity, dying cells (apoptotic bodies) and rare mitoses. Other cystic glands were lined by inactive epithelium.The pathologists described this constellation of cysts and epithelial findings as “novel,” noting that they are sufficiently different from what has been seen in clinical practice that their long term behavior cannot be precisely predicted without performing serial biopsies in future extended studies."
I think the FDA will require a larger long term pivotal trial then is currently planned since I can't imagine the FDA not being extremely careful considering the "novel" findings. Wasn't the Asoprisnil Phase III trial going to be a 2 or 3 yr. study?
Bailout - Bush will let the FHA guarantee loans for delinquent borrowers (those 90 days late), allowing them to avoid foreclosure and refinance at more favorable rates.
So basically we're going to let the derelicts live in their homes for as long as they want and the government will make the mortgage payments.
You may have made money, but you wouldn't have made a dime by following their advise on the stock.
OT- BSR, they get my award for the worse market timing. They advised not getting excited about a certain stock yesterday and it was up 18% at one point today. I'm starting to wonder if these guys are working for me or against me?